Skip to main content

Table 3 Total meta-analysis outcomes and stratified analysis of each endpoint based on study design and duration of follow-up

From: Clinical outcome comparison of percutaneous coronary intervention and bypass surgery in diabetic patients with coronary artery disease: a meta-analysis of randomized controlled trials and observational studies

Endpoints

Subgroup

Study, n

RR

95% CI

Pvalue

I2 (%)

Pheterogeneity

All-cause death

Total

15

1.23

1.00–1.52

0.05

77

< 0.001

RCT

6

1.30

0.86–1.98

0.08

70

0.005

OS

9

1.22

0.95–1.56

0.12

81

< 0.001

Mid-term

7

1.12

0.76–1.65

0.58

61

0.02

Long-term

8

1.32

1.04–1.67

0.02

82

< 0.001

MACCE

Total

8

1.59

1.38–1.85

< 0.001

68

0.003

RCT

5

1.40

1.20–1.63

< 0.001

26

0.25

OS

3

1.87

1.72–2.03

< 0.001

0

0.52

Mid-term

3

1.31

1.11–1.54

0.001

14

0.31

Long-term

5

1.84

1.70–1.99

< 0.001

0

0.58

Cardiac death

Total

7

1.76

1.11–2.80

0.02

71

0.002

RCT

4

2.25

1.28–3.98

0.005

65

0.04

OS

3

1.20

0.92–1.56

0.18

0

0.93

Mid-term

4

1.99

0.96–4.15

0.07

70

0.02

Long-term

3

1.37

0.99–1.90

0.06

18

0.30

MI

Total

11

1.98

1.53–2.57

< 0.001

64

0.002

RCT

5

1.35

0.97–1.86

0.07

42

0.14

OS

6

2.44

2.07–2.88

< 0.001

3

0.40

Mid-term

5

1.53

0.95–2.48

0.08

69

0.01

Long-term

6

2.35

2.01–2.73

< 0.001

0

0.61

Stroke

Total

12

0.71

0.48–1.03

0.07

66

< 0.001

RCT

6

0.44

0.27–0.71

< 0.001

0

0.76

OS

6

0.95

0.62–1.45

0.81

72

0.003

Mid-term

6

0.39

0.23–0.66

< 0.001

0

0.86

Long-term

6

0.95

0.64–1.41

0.79

72

0.004

Repeat revascularization

Total

12

2.61

2.08–3.29

< 0.001

79

< 0.001

RCT

5

2.22

1.46–3.39

< 0.001

78

0.001

OS

7

2.92

2.21–3.87

< 0.001

79

< 0.001

Mid-term

6

2.88

1.66–4.99

< 0.001

84

< 0.001

Long-term

6

2.56

2.02–3.24

< 0.001

75

0.001

  1. Italic values indicate significance of P value (Pvalue and Pheterogeneity < 0.05)
  2. RR risk ratio, CI confidence intervals, MACCE major adverse cardiac and cerebrovascular event, MI myocardial infarction, RCT randomized controlled trials, OS observational studies, Mid-term 1–3 years follow-up, Long-term > 3 years follow-up